Suppr超能文献

采用开放和闭合腹部技术对结直肠癌腹膜转移和腹膜假黏液瘤复发进行重复细胞减灭术和热灌注化疗:来自六个法国专家中心的结果

Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Using Open and Closed Abdomen Techniques for Colorectal Peritoneal Metastases and Peritoneal Pseudomyxoma Recurrences: Results from Six French Expert Centers.

作者信息

Tidadini Fatah, Arvieux Catherine, Glehen Olivier, Sourrouille Isabelle, Marchal Frédéric, Abba Julio, Malgras Brice, Quesada Jean-Louis, Pocard Marc, Ezanno Anne-Cécile

机构信息

Department of Digestive and Emergency Surgery, Grenoble-Alpes University Hospital, Grenoble, France.

Lyon Center for lnnovation in Cancer, Lyon 1 University, Lyon, France.

出版信息

Ann Surg Oncol. 2025 Jan;32(1):209-220. doi: 10.1245/s10434-024-16407-1. Epub 2024 Nov 4.

Abstract

BACKGROUND

Standard treatment for resectable peritoneal metastases (PM) combines cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC); however, the rate of recurrence remains high and repeat CRS/HIPEC may be considered in well-selected patients. We describe our postoperative and oncological outcomes.

METHODS

Between 1994 and 2024, data from 132 repeat CRS/HIPEC procedures were analyzed in this retrospective multicenter study. Morbimortality, overall survival (OS) and recurrence-free survival (RFS) were evaluated for colorectal peritoneal metastases (CRPM) and peritoneal pseudomyxoma (PMP).

RESULTS

Overall, 63 patients, including 55 patients with CRPM (87.3%) and 8 patients with PMP (12.7%), underwent CRS/HIPEC. Of these patients, 58 (92%) underwent CRS/HIPEC twice, 4 (6.3%) underwent CRS/HIPEC three times, and 1 (1.6%) underwent CRS/HIPEC four times. Peritoneal Carcinomatosis Index (PCI) score, operating room occupancy, complication and readmission rates at day 90, and length of intensive care unit and hospital stay were similar between the initial and first repeat CRS/HIPEC procedures. No 90-day postoperative mortality occurred. For CRPM, the median OS was 82.3, 53.9, and 74.5 months from the initial, first, and second repeat CRS/HIPEC procedures, respectively, with a median RFS of 22.0, 36.9, and 13.2 months, respectively. For PMP, after a median follow-up of 70.8 and 39.3 months from the initial and first repeat CRS/HIPEC procedures, respectively, all patients were alive, with a median RFS of 22.4 and 39.4 months, respectively. Multivariate analysis shown that no factor was significantly related to severe complications (Dindo-Clavien 3-4) or OS.

CONCLUSIONS

In selected patients with CRPM and PMP, CRS/HIPEC shows comparable results between the initial and repeat procedures in terms of postoperative outcomes, and appears to improve survival, especially for PMP. Repeat CRS/HIPEC is an option to be considered in patients presenting with CRPM or PMP.

摘要

背景

可切除性腹膜转移瘤(PM)的标准治疗是细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC);然而,复发率仍然很高,对于精心挑选的患者可考虑再次进行CRS/HIPEC。我们描述了我们的术后及肿瘤学结局。

方法

在这项回顾性多中心研究中,分析了1994年至2024年间132例再次进行CRS/HIPEC手术的数据。对结直肠癌腹膜转移瘤(CRPM)和腹膜假黏液瘤(PMP)的手术死亡率、总生存期(OS)和无复发生存期(RFS)进行了评估。

结果

总体而言,63例患者接受了CRS/HIPEC,其中包括55例CRPM患者(87.3%)和8例PMP患者(12.7%)。在这些患者中,58例(92%)接受了两次CRS/HIPEC,4例(6.3%)接受了三次CRS/HIPEC,1例(1.6%)接受了四次CRS/HIPEC。初次与首次再次进行CRS/HIPEC手术之间的腹膜癌指数(PCI)评分、手术室占用时间、90天时的并发症和再入院率,以及重症监护病房和住院时间相似。术后90天内无死亡病例。对于CRPM,初次、首次和第二次再次进行CRS/HIPEC手术后的中位OS分别为82.3、53.9和74.5个月,中位RFS分别为22.0、36.9和13.2个月。对于PMP,初次和首次再次进行CRS/HIPEC手术后的中位随访时间分别为70.8和39.3个月,所有患者均存活,中位RFS分别为22.4和39.4个月。多因素分析显示,没有因素与严重并发症(Dindo-Clavien 3 - 4级)或OS显著相关。

结论

在选定的CRPM和PMP患者中,CRS/HIPEC在初次和再次手术的术后结局方面显示出可比的结果,并且似乎能改善生存,尤其是对于PMP。对于出现CRPM或PMP的患者,再次进行CRS/HIPEC是一个可考虑的选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验